<http://schema.org/description>
"Clinical-stage biotechs are frequently targeted by short-sellers because these types of companies can (and sometimes do) crater overnight. By the same token, a positive clinical or regulatory"^^<http://www.w3.org/2001/XMLSchema#string>
<http://www.aol.com/article/2014/07/02/are-investors-wrong-about-newlink-genetics/20924379/>